Celularity Inc. Class A CELU 深 滬
等待開盤 08-10 09:30:00 美东时间
0.7007
+0.018
+2.59%
華盛通- 最 高0.7325
- 今 開0.6898
- 成交量 1.81万股
- 最 低 0.6897
- 昨 收 0.683
- 總市值 2028.24万
- 52周最高 4.31
- 市盈率 靜 --
- 換手率 0.06%
- 52周最低 0.5601
- 委 比 34.23%
- 總股本 2894.60万
- 歷史最高 134.00
- 量 比 0.40
- 振 幅 6.27%
- 歷史最低 0.5601
- 每 手 1
- 風險率 0.75%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Celularity Receives Nasdaq Noncompliance Notice
- Celularity Inc. (NASDAQ:CELU) (the "Company"), a longevity-focused regenerative and cellular medicine company, today announced that it received a notification letter on May 27, 2026, from the Listing Qualifications
05-30 05:17
Celularity Enters Settlement With Helena Global To Restructure Convertible Note Obligations, Including $500K Upfront And $100K Monthly Payments Plus Note Assignment
Entry into a Material Definitive Agreement. As previously disclosed by Celularity Inc. (the "Company") in its Current Report on Form 8-K filed on April 21, 2026, Helena Global Investment Opportunities 1 Ltd.
05-29 05:24
美股夜盘 | Cabaletta Bio涨17.35%，Freshpet Inc涨16.04%
阿卡迪亚医疗保健涨-14.11%；Akanda Corp涨-10.28%；联掌门户涨-9.43%
05-04 08:05
Celularity Receives Nasdaq Notice Regarding Late Form 10-K Filing
Celularity Inc. (NASDAQ:CELU) (the "Company"), a longevity-focused regenerative and cellular medicine company, today announced that on April 16, 2026, the Company received notification from the Listing Qualifications
04-18 04:38
Celularity Signs $35M Agreements For Its Placental-Derived Biomaterials Portfolio
Celularity Inc. (Nasdaq: CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company focused on longevity science, today announced that it has entered into definitive agreements establishing a
03-10 20:32
EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue
NexGel to acquire Celularity biomaterial products, a deal expected to triple revenue to $35 million and make the company profitable.
03-10 20:30
Celularity Receives $12.2M In Net Cash Proceeds From Sale Of ~$126.3M Of Unused New Jersey NOLs And $1.9M Of Unused New Jersey R&D Tax Credits
Celularity Inc. (NASDAQ:CELU) ("Celularity"), a longevity-focused regenerative and cellular medicine company, today announced receipt of $12.2 Million in net cash proceeds from the sale of approximately $126.3 Million of
02-10 21:43
Celularity Files Prospectus For The Offering Of Up To 14.1M Shares Of Class A Common Stock
Celularity Inc. Up to 14,078,938 shares of Class A Common Stock Pursuant to this prospectus, the selling stockholders identified herein (the "Selling Stockholders") are offering on a resale basis an aggregate
01-01 05:19
